

REMARKS

Applicants would like to express their sincere gratitude to Examiner Anne R. Kubelik for answering Applicants' questions. After careful review of the documents submitted to the US Patent and Trademark Office on May 24, 2002, it was noticed that the computer readable form copy of the sequence listing does not contain accurate general information. Accordingly, it has been considered appropriate to submit paper and computer readable form copies of the Sequence Listing along with the current response.

The Specification has been amended to include SEQ ID numbers, which were inadvertently omitted at the time of filing.

Attached hereto is a marked-up version of the changes made to the specification by the current amendment. The attached page is captioned "Version with markings to show changes made.".


The undersigned hereby states that the computer readable form copy (CFR copy) of the Sequence Listing and the paper copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.825(a) and (b), respectively, are the same and contain no new matter. Accordingly, entry of the Sequence Listing into the above-captioned case is respectfully requested.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 278012001420. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Respectfully submitted,

Dated: October 16 , 2002

By:



Irina E. Brieva
Registration No. 50,498

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-5175
Facsimile: (858) 720-5125

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

The paragraph beginning at page 87, line 1 has been amended as follows:

The following provides details of a typical construction of a zinc finger, in this case, construction of ZFPm2: The following primers were used to construct the ZFPm2a protein: F1-f1 (ggt aag tcc ttc AGC CGC AGC GAT AAC CTG GTG CGC cac cag cgt acc cac acg ggt gaa aaa ccg tat aaa tgc cca gag) (SEQ ID NO: 67), F1-f2 (gag gag gag gag gtg gcc cag gcg gcc ctc gag ccc ggg gag aag ccc tat gct tgt ccg gaa tgt ggt aag tcc ttc AGC CGC AGC) (SEQ ID NO: 68), F2-f (GC CAG GCC GGC CAC CTG GCC AGC cat caa cgc act cat act ggc gag aag cca tac aaa tgt cca gaa tgt ggc) (SEQ ID NO: 69), F2-b (GCT GGC CAG GTG GCC GGC CTG GCT aaa aga ttt gcc gca ctc tgg gca ttt ata cgg ttt ttc acc) (SEQ ID NO: 70), F3-b1 (CCG GAC GAG ATT GTC AGA CCG AGA gaa aga ctt gcc aca ttc tgg aca ttt gta tgg c) (SEQ ID NO: 71), F3-b2 (gag gag gag gag ctg gcc ggc ctg gcc act agt ttt ttt acc ggt gtg agt acg ttg gtg CCG GAC GAG ATT GTC AGA CCG) (SEQ ID NO: 72). These primers were used as described above to generate the 3-finger protein, ZFPm2a (SEQ ID NO:63):

1	gaggaggagg aggtggccca ggcggccctc gagcccgagg agaagcccta	50
51	tgcttgccg gaatgtgta agtccttcAG CCGCAGCGAT AACCTGGTGC	100
101	GCcaccagcg tacccacacg ggtgaaaaac cgtataaatg cccagagtgc	150
151	ggcaaatctt ttAGCCAGGC CGGCCACCTG GCCAGCcatc aacgcactca	200
201	tactggcgag aagccataca aatgtccaga atgtggcaag tctttcTCTC	250
251	GGTCTGACAA TCTCGTCCGG caccaacgta ctcacaccgg taaaaaaact	300
301	agtggccagg ccggccagct cctcctcctc	330